<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00385931</url>
  </required_header>
  <id_info>
    <org_study_id>CVAS489A2301</org_study_id>
    <nct_id>NCT00385931</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin</brief_title>
  <official_title>A Multi-centre Study to Evaluate the Effects of Valsartan and the Combination of Valsartan and Simvastatin on Blood Pressure (Ambulatory and Std Cuff) and on Biochemical Markers of Endothelial Function (hsCRP, MCP-1, Serum F2 Isoprostanes, PAI-1, tPA, PICP, PIIINP, MMP9, MMP1, TIMP 1), Safety and Tolerability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess and compare the efficacy and safety of valsartan and the combination
      of valsartan and simvastatin in patients with high blood pressure and high cholesterol.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">April 2003</completion_date>
  <primary_completion_date type="Actual">April 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in ambulatory systolic blood pressure at 12 weeks</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline at 12 weeks for ambulatory diastolic blood pressure, systolic and diastolic blood pressure (std cuff), day and nighttime blood pressures, biochemical markers of endothelial function &amp; lipid levels</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
  </secondary_outcome>
  <enrollment type="Actual">412</enrollment>
  <condition>Hypertension</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Dyslipidemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan and simvastatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients at least 50 years of age

          -  Mild to moderate essential systolic hypertension (grades 1 and 2 WHO classification)
             defined as MSSBP ≥ 150 mmHg and &lt;180mmHg

          -  Simultaneous primary hypercholesterolemia or mixed dislipidemia (Fredrickson Types IIa
             and IIb) defined by LDL-C level ≥ 130 mg/dL and &lt;190 mg/dL and triglyceride levels ≤
             400 mg/dL despite dietary therapy

          -  Off medication at randomization

        Exclusion Criteria:

          -  Severe hypertension (grade 3 WHO classification

          -  ≥ 180 mm Hg systolic or ≥ 110 mm Hg (diastolic)

          -  secondary form of hypertension

          -  known Keith-Wagener Grade III or IV hypertensive retinopathy

          -  history of hypertensive encephalopathy or cerebrovascular accident within the
             preceding 12 months

          -  transient ischemic cerebral attack during the preceding 6 months

          -  dyslipidemia secondary to other causes

          -  Type 1 diabetes mellitus

          -  Type 2 diabetes mellitus with poor glucose control

          -  history of systemic inflammatory diseases

          -  serum CK more than twice ULN

          -  sodium depletion

          -  malignancy in preceding 5 years history of heart failure

          -  myocardial infarction within the preceding 12 months

          -  second or third degree heart block

          -  concomitant refractory angina pectoris

          -  symptomatic arrhythmia

          -  valvular heart disease

          -  Any condition/surgery that may alter absorption, distribution, metabolism, excretion
             of any drug (e.g. history of major gastrointestinal tract surgery, inflammatory bowel
             syndrome, pancreatic dysfunction, impaired renal or liver function)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>East Hanover</city>
        <state>New Jersey</state>
        <zip>07936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2006</study_first_submitted>
  <study_first_submitted_qc>October 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2006</study_first_posted>
  <last_update_submitted>November 7, 2011</last_update_submitted>
  <last_update_submitted_qc>November 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>high cholesterol</keyword>
  <keyword>valsartan</keyword>
  <keyword>simvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

